IDEXX Laboratories (MEX:IDXX) Cyclically Adjusted Revenue per Share: MXN735.82 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:IDXX IDEXX Laboratories Inc MEX:IDXX
96 GF Score
Price MXN9,650.00
GF Value MXN11,091.34
Valuation Modestly Undervalued
View Full Analysis

What is IDEXX Laboratories Cyclically Adjusted Revenue per Share?

IDEXX Laboratories MEX:IDXX 96 Cyclically Adjusted Revenue per Share is MXN735.82 as of Mar. 2026. GuruFocus rates MEX:IDXX with a GF Score™ of 96/100 and a GF Value™ of MXN11,091.34 (Modestly Undervalued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

IDEXX Laboratories's adjusted revenue per share for the three months ended in Mar. 2026 was MXN256.631. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN735.82 for the trailing ten years ended in Mar. 2026.

During the past 12 months, IDEXX Laboratories's average Cyclically Adjusted Revenue Growth Rate was 11.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 14.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 14.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of IDEXX Laboratories was 16.30% per year. The lowest was 11.80% per year. And the median was 13.70% per year.

As of today (2026-08-03), IDEXX Laboratories's current stock price is MXN9650.00. IDEXX Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN735.82. IDEXX Laboratories's Cyclically Adjusted PS Ratio of today is 13.11.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of IDEXX Laboratories was 30.79. The lowest was 8.56. And the median was 14.78.


IDEXX Laboratories  (MEX:IDXX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

IDEXX Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=9650.00/735.82
=13.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of IDEXX Laboratories was 30.79. The lowest was 8.56. And the median was 14.78.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


IDEXX Laboratories Cyclically Adjusted Revenue per Share Related Terms


IDEXX Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for IDEXX Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDEXX Laboratories Cyclically Adjusted Revenue per Share Chart

IDEXX Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 480.88 557.89 547.30 719.17 725.40

IDEXX Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 752.32 711.19 704.36 725.40 735.82

MEX:IDXX vs A, NTRA, WAT: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, IDEXX Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDEXX Laboratories Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where IDEXX Laboratories's Cyclically Adjusted PS Ratio falls into.


MEX:IDXX
96GF Score
IDEXX Laboratories Inc MEX:IDXX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IDEXX Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, IDEXX Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=256.631/330.2130*330.2130
=256.631

Current CPI (Mar. 2026) = 330.2130.

IDEXX Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 95.010 241.018 130.171
201609 95.111 241.428 130.088
201612 100.746 241.432 137.793
201703 96.666 243.801 130.928
201706 102.357 244.955 137.983
201709 100.031 246.819 133.829
201712 111.606 246.524 149.494
201803 109.821 249.554 145.317
201806 128.804 251.989 168.788
201809 115.345 252.439 150.882
201812 122.834 251.233 161.449
201903 127.635 254.202 165.800
201906 135.953 256.143 175.267
201909 136.310 256.759 175.306
201912 130.845 256.974 168.137
202003 169.383 258.115 216.696
202006 170.331 257.797 218.178
202009 183.932 260.280 233.352
202012 164.870 260.474 209.012
202103 182.900 264.877 228.015
202106 189.780 271.696 230.654
202109 192.621 274.310 231.876
202112 190.751 278.802 225.925
202203 194.667 287.504 223.585
202206 204.017 296.311 227.359
202209 201.277 296.808 223.930
202212 192.706 296.797 214.403
202303 193.261 301.836 211.430
202306 192.628 305.109 208.477
202309 189.867 307.789 203.700
202312 182.316 306.746 196.264
202403 190.578 312.332 201.489
202406 220.470 314.175 231.725
202409 231.274 315.301 242.212
202412 241.094 315.605 252.253
202503 249.335 319.799 257.454
202506 257.923 322.561 264.042
202509 251.314 324.800 255.502
202512 243.997 324.054 248.634
202603 256.631 330.213 256.631

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN735.82 mean?
IDEXX Laboratories (MEX:IDXX) has a Cyclically Adjusted Revenue per Share of MXN735.82 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on IDEXX Laboratories and its competitors.
Is IDEXX Laboratories' Cyclically Adjusted Revenue per Share too high?
IDEXX Laboratories' current Cyclically Adjusted Revenue per Share is MXN735.82. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Cyclically Adjusted Revenue per Share compare to A and NTRA?
IDEXX Laboratories' Cyclically Adjusted Revenue per Share of MXN735.82 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on IDEXX Laboratories and its competitors. IDEXX Laboratories's current Cyclically Adjusted Revenue per Share is MXN735.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (MEX:IDXX) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN11,091.34, compared to a current price of MXN9,650.00 — trading 13% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN735.82. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For IDEXX Laboratories (MEX:IDXX), the current Cyclically Adjusted Revenue per Share is MXN735.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IDEXX Laboratories (MEX:IDXX) Overvalued in 2026?

Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued. The current stock price of MXN9,650.00 is trading 13% below its estimated GF Value™ of MXN11,091.34. GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.

Key valuation signals for MEX:IDXX:

  • Cyclically Adjusted Revenue per Share: MXN735.82
  • GF Value™: MXN11,091.34 vs. price of MXN9,650.00 (13% below fair value)
  • GF Score™: 96/100

No single metric tells the full story. See the MEX:IDXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


IDEXX Laboratories Business Description

Address One IDEXX Drive, Westbrook, ME, USA, 04092
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score

Get the complete analysis for MEX:IDXX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN9,650.00
Price
MXN11,091.34
GF Value